Market Overview

Abbott Receives Positive Opinion from CHMP for HUMIRA Use in Pediatric Crohn's Disease

Share:
Related ABT
Benzinga's M&A Chatter for Thursday August 27, 2015
Benzinga's Volume Movers
Can Top 10 Healthcare Dogs Average 25% Upsides And 27% Net Gains As Of September 2016? (Seeking Alpha)

Abbott (NYSE: ABT) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for HUMIRA® (adalimumab) for the treatment of pediatric patients aged six to 17 years with severely active Crohn's disease (CD) who failed, are intolerant to or have contraindications to conventional therapy. Following the CHMP's positive opinion, a final decision from the European Commission is anticipated in the next several weeks. Upon final decision, HUMIRA will be the only biologic in the European Union (EU) for the treatment of pediatric CD offering at-home administration.

Pediatric CD is a chronic, debilitating condition of the gastrointestinal (GI) tract that affects up to 200,000 children worldwide(i,ii) CD most commonly involves the end of the small intestine and the beginning of the large intestine.(iii) In addition to symptoms such as chronic abdominal pain, weight loss and loose stools(i) pediatric CD can affect children in several ways, including potentially contributing to malnutrition, failure to grow and/or delayed puberty.(i,iv)

Posted-In: News FDA

 

Related Articles (ABT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters